Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody ; volume:16 ; number:1 ; day:12 ; month:9 ; year:2018 ; pages:1-13 ; date:12.2018
Journal of translational medicine ; 16, Heft 1 (12.9.2018), 1-13, 12.2018
- Creator
-
Kou, Jianqun
- Contributor
-
Musich, Phillip R.
Staal, Ben
Kang, Liang
Qin, Yuan
Yao, Zhi Q.
Zhang, Boheng
Wu, Weizhong
Tam, Angela
Huang, Alan
Hao, Huai-Xiang
Vande Woude, George F.
Xie, Qian
SpringerLink (Online service)
- DOI
-
10.1186/s12967-018-1628-y
- URN
-
urn:nbn:de:101:1-2018102819193927781408
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kou, Jianqun
- Musich, Phillip R.
- Staal, Ben
- Kang, Liang
- Qin, Yuan
- Yao, Zhi Q.
- Zhang, Boheng
- Wu, Weizhong
- Tam, Angela
- Huang, Alan
- Hao, Huai-Xiang
- Vande Woude, George F.
- Xie, Qian
- SpringerLink (Online service)
Other Objects (12)
Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
In vitro effectiveness of CB469, a MET tyrosine kinase inhibitor in MET-activated cancer cells
Rückweisungen 1953 - 1979: Met - Met
A receptor-antibody hybrid hampering MET-driven metastatic spread
"Met"
"MET"
Met
Met
Met
met
Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
In vitro effectiveness of CB469, a MET tyrosine kinase inhibitor in MET-activated cancer cells
Rückweisungen 1953 - 1979: Met - Met
A receptor-antibody hybrid hampering MET-driven metastatic spread
"Met"
"MET"
Met
Met
Met
met
Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
In vitro effectiveness of CB469, a MET tyrosine kinase inhibitor in MET-activated cancer cells
Rückweisungen 1953 - 1979: Met - Met
A receptor-antibody hybrid hampering MET-driven metastatic spread
"Met"
"MET"
Met
Met
Met